Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
As healthcare costs continue to rise, accurate cost-effectiveness estimates are crucial. However, estimating the costs and outcomes of different interventions is complicated by uncertainty.
In model-based health economic evaluations (HEEs), uncertainty can arise from limited data, methodological limitations, and variability in clinical outcomes.
A recent review identified 80 methods for identifying, analyzing, and communicating uncertainty in HEEs. Quantifying uncertainty wherever possible is crucial to ensure accurate and unbiased cost-effectiveness estimates, ultimately leading to optimal allocation of healthcare resources
Recent Posts
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Portugal's Epidyolex spending has topped €3 million since 2021, fueling debates on access to this CBD-based epilepsy drug through the National Health Service (SNS). If you're wondering how this impacts patient care and healthcare costs, the answer lies in Infarmed's nearly four-year evaluation fo...
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry Transformation
The fourth edition of the Global Pharma Executive Course runs from March to May 2026 at Portugal's Faculdade de Medicina da Universidade Católica Portuguesa and Hospital da Luz Lisboa. The course targets pharma industry leaders, as rapid changes driven by tech advances, therapeutic innovation, an...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for Cost Reduction and U...
Johnson & Johnson has reached a landmark medicine access agreement with the U.S. government, aimed at broadening access to its pharmaceutical products and slashing costs for millions of American patients. Under this voluntary arrangement during the Trump Administration, the company's medicine...